COGT Earnings & Financial Statements
Cogent Biosciences, Inc.
$29.15
+$1.00(+3.53%)
32
Overall
40
Value
18
Tech
39
Quality
Market Cap
$4.88B
Volume
656.54K
52W Range
$13.78 - $43.73
Target Price
$55.82
COGT earnings and financial statements: Cogent Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
COGT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $950.0K | $2.62M | $2.47M |
| Operating income | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -$75.55M |
| EBITDA | -$320.69M | -$251.51M | -$188.82M | -$134.41M | -$73.56M |
| Net income | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -$72.27M |
| EPS (diluted) | $-2.16 | $-1.94 | $-2.42 | $-2.39 | $-1.87 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $937.61M | $327.90M | $313.44M | $300.81M | $232.09M |
| Total liabilities | $301.24M | $71.61M | $55.63M | $45.08M | $17.91M |
| Shareholders’ equity | $636.37M | $256.29M | $257.80M | $255.74M | $214.18M |
| Cash and equivalents | $312.01M | $98.17M | $53.23M | $139.89M | $219.68M |
| Long-term debt | $237.25M | $15.90M | $17.47M | $18.23M | $831.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$264.44M | -$207.79M | -$153.62M | -$118.64M | -$58.76M |
| Capital expenditure | -$1.55M | -$573.0K | -$2.80M | -$6.86M | -$1.72M |
| Free cash flow | -$266.00M | -$208.36M | -$156.42M | -$125.50M | -$60.48M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | COGT | $29.15 | +3.5% | 656.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cogent Biosciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW